Comparison of incidence (Figure 1A) and severity grade of DILI in study participants stratified by treatment groups: HIV patients without TB co-infection (Arm-1) treated with efavirenz based HAART alone, TB-HIV co-infected patients with CD4 count ≤ 200 cells/μL treated with concomitant anti-TB and HAART therapy (Arm-2), TB-HIV co-infected patients with CD4 count >200 cells/μL treated with anti-TB therapy alone (Arm-3) and TB patients without HIV co-infection treated anti-TB therapy alone (Arm-4).

<p>Figure 1B indicates severity grade distribution among the total 159 DILI cases.</p

Univariate and Multivariate Cox proportional regression analysis to show the risk factors for developing DILI. HR = hazard ratio.

<p>Univariate and Multivariate Cox proportional regression analysis to show the risk factors for developing DILI. HR  =  hazard ratio.</p

Distribution of the different types of liver injuries (hepatocellular, cholestatic and mixed type) that were observed in each treatment group (Figure 2A) and stratified by severity grade (Figure 2B): HIV patients without TB co-infection (Arm-1) treated with efavirenz based HAART alone, TB-HIV co-infected patients with CD4 count ≤ 200 cells/μL treated with concomitant anti-TB and HAART therapy (Arm-2), TB-HIV co-infected patients with CD4 count >200 cells/μL treated with anti-TB therapy alone (Arm-3) and TB patients without HIV co-infection treated anti-TB therapy alone (Arm-4).

<p>Distribution of the different types of liver injuries (hepatocellular, cholestatic and mixed type) that were observed in each treatment group (Figure 2A) and stratified by severity grade (Figure 2B): HIV patients without TB co-infection (Arm-1) treated with efavirenz based HAART alone, TB-HIV co-infected patients with CD4 count ≤ 200 cells/μL treated with concomitant anti-TB and HAART therapy (Arm-2), TB-HIV co-infected patients with CD4 count >200 cells/μL treated with anti-TB therapy alone (Arm-3) and TB patients without HIV co-infection treated anti-TB therapy alone (Arm-4).</p

Socio demographic, type of HAART, baseline clinical and laboratory characteristics of study participants stratified by treatment groups.

<p>Arm1  =  HIV patients treated with efavirenz based HAART only.</p><p>Arm2  =  TB-HIV patients with baseline CD4<200 cells/μL, treated with efavirenz based HAART and rifampicin based anti-tuberculosis drugs.</p><p>Arm3  =  TB-HIV patients with baseline CD4>200 cells/μL, treated with rifampicin based anti-tuberculosis drugs only,</p><p>Arm4  =  TB patients treated with rifampicin based anti-tuberculosis drugs only.</p

Comparison on incidence, type and severity grade of antiretroviral and/or antituberculosis DILI stratified by type of disease and treatment groups.

<p>Arm1  =  HIV patients treated with efavirenz based HAART only.</p><p>Arm2  =  TB-HIV patients with baseline CD4<200 cells/μL, treated with efavirenz based HAART and rifampicin based anti-tuberculosis drugs.</p><p>Arm3  =  TB-HIV patients with baseline CD4>200 cells/μL, treated with rifampicin based anti-tuberculosis drugs only,</p><p>Arm4  =  TB patients treated with rifampicin based anti-tuberculosis drugs only.</p

Additional file 1: Table S1. of Genome-wide association and replication study of anti-tuberculosis drugs-induced liver toxicity

Top fifteen SNPs in the GWAS of ATDILI. Table S2. Top fifteen SNPs in the replication study of ATDILI. Table S3. Top SNPs in the GWAS of the pattern of ATDILI. Table S4. Top SNPs for GWAS of ATDILI in genes related to autoimmune diseases, oxidative stress, pharmacokinetic, and HLA region. (PDF 57 kb

Performances of DILI-ActiTest, apoA1 and haptoglobin, for the prediction of recovery.

<p>DILI-ActiTest ‘s AUROC = 0.723 (95%CI 0.610–0.806 P<0.001 vs. 0.5). The AUROCs of APOA1, and HAPTO were 0.663 (0.536–0.76; P = 0.004 vs 0.5; P = 0.14 vs DILI-ActiTest), and 0.619 (0.496–0.718; P = 0.04 vs 0.500; p = 0.05 vs DILI-ActiTest).</p

Characteristics of patients adjudicated as DILI or not, among the population suspected cases, the context of use population (n = 176).

<p>Characteristics of patients adjudicated as DILI or not, among the population suspected cases, the context of use population (n = 176).</p

Summary of significant (Bonferroni) differences of baseline test medians according to drugs, n = 154.

<p>Summary of significant (Bonferroni) differences of baseline test medians according to drugs, n = 154.</p

Prediction of recovery at inclusion, in adjudicated DILI cases (n = 115).

<p>Prediction of recovery at inclusion, in adjudicated DILI cases (n = 115).</p